The Effect of Excipients on the Permeability of BCS Class for Biowaivers

Pharmaceutical Research 33, 167-176 DOI: 10.1007/s11095-015-1773-4

Citation Report

#	Article	IF	CITATIONS
1	A Mixed Micelle Formulation for Oral Delivery of Vitamin K. Pharmaceutical Research, 2016, 33, 2168-2179.	3.5	37
2	Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker ⁵¹ Cr-EDTA. Molecular Pharmaceutics, 2017, 14, 4243-4251.	4.6	34
3	Biopharmaceutical aspects and implications of excipient variability in drug product performance. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 111, 1-15.	4.3	75
4	Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound. Scientific Reports, 2018, 8, 1925.	3.3	14
5	Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis. Molecular Pharmaceutics, 2018, 15, 2633-2645.	4.6	9
6	Mixed micellar system stabilized with saponins for oral delivery of vitamin K. Colloids and Surfaces B: Biointerfaces, 2018, 170, 521-528.	5.0	16
7	Dissolution Profile Consideration in Pharmaceutical Product Development. , 2018, , 287-336.		3
8	Glycerol Solvates DPPC Headgroups and Localizes in the Interfacial Regions of Model Pulmonary Interfaces Altering Bilayer Structure. Langmuir, 2018, 34, 6941-6954.	3.5	25
9	The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs. International Journal of Pharmaceutics, 2018, 547, 158-168.	5.2	38
10	Rat intestinal drug permeability: A status report and summary of repeated determinations. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 364-376.	4.3	11
11	Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets. Frontiers in Pediatrics, 2019, 7, 281.	1.9	2
12	Solvent driven phase transitions of acyclovir – the role of water and solvent polarity. CrystEngComm, 2019, 21, 2180-2192.	2.6	8
13	Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 130-138.	4.3	39
14	The Discriminatory Power of the BCS-Based Biowaiver: AÂRetrospective With Focus on Essential Medicines. Journal of Pharmaceutical Sciences, 2019, 108, 2824-2837.	3.3	18
15	Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines. Journal of Pharmacy and Pharmacology, 2019, 71, 1231-1242.	2.4	23
16	Effect of intra- and extragranular addition of highly porous tribasic calcium phosphate on properties of immediate release acyclovir formulation – Comparison with commercial tablets using compendial and biorelevant dissolution methods. Journal of Drug Delivery Science and Technology, 2019, 51, 464-474.	3.0	3
17	11. Biowaivers. , 2019, , 319-352.		0
18	Employing a PLGA-TPGS based nanoparticle to improve the ocular delivery of Acyclovir. Saudi Pharmaceutical Journal, 2019, 27, 293-302.	2.7	44

#	Article	IF	CITATIONS
19	3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 138, 99-110.	4.3	53
20	Prompt drug delivery of rabeprazole through raft formation: In vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology, 2020, 60, 101932.	3.0	4
21	N,N,N-trimethylchitosan-poly (n-butylcyanoacrylate) core-shell nanoparticles as a potential oral delivery system for acyclovir. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111336.	5.0	3
22	Effect of excipients on oral absorption process according to the different gastrointestinal segments. Expert Opinion on Drug Delivery, 2021, 18, 1005-1024.	5.0	8
23	Acyclovir-Loaded Solid Lipid Nanoparticles: Optimization, Characterization and Evaluation of Its Pharmacokinetic Profile. Nanomaterials, 2020, 10, 1785.	4.1	15
24	Effect of Common Excipients on Intestinal Drug Absorption in Wistar Rats. Molecular Pharmaceutics, 2020, 17, 2310-2318.	4.6	8
25	The Effect of Anesthetic Regimens on Intestinal Absorption of Passively Absorbed Drugs in Rats. Pharmaceutical Research, 2020, 37, 87.	3.5	2
26	Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help. Biopharmaceutics and Drug Disposition, 2021, 42, 118-127.	1.9	11
27	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. Journal of Pharmaceutical Sciences, 2021, 110, 1513-1526.	3.3	8
28	A differential equation based modelling approach to predict supersaturation and in vivo absorption from in vitro dissolution-absorption system (idas2) data. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 1-12.	4.3	9
29	An Assessment of Occasional Bio-Inequivalence for BCS1 and BCS3 Drugs: What are the Underlying Reasons?. Journal of Pharmaceutical Sciences, 2021, , .	3.3	1
30	Understanding Conformational Polymorphism in Ganciclovir: A Holistic Approach. Chemistry, 2021, 3, 126-137.	2.2	1
31	Effect of sex and food on the pharmacokinetics of different classes of BCS drugs in rats after cassette administration. International Journal of Pharmaceutics, 2021, 610, 121221.	5.2	5
32	Evaluation of Excipient Risk in BCS Class I and III Biowaivers. AAPS Journal, 2022, 24, 20.	4.4	16
33	The involvement of extracellular vesicles in the transcytosis of nanoliposomes through brain endothelial cells, and the impact of liposomal pH-sensitivity. Materials Today Bio, 2022, 13, 100212.	5.5	4
34	Exploring the Predictive Power of the <i>In Situ</i> Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. Molecular Pharmaceutics, 2022, 19, 749-762.	4.6	3
35	Preclinical Pharmacokinetic Studies of a Novel Diuretic Inhibiting Urea Transporters. Molecules, 2022, 27, 2451.	3.8	1
37	Lack of an Effect of Polysorbate 80 on Intestinal Drug Permeability in Humans. Pharmaceutical Research, 2022, 39, 1881-1890.	3.5	7

CITATION REPORT

#	Article	IF	CITATIONS
38	Comparator product issues for biowaiver implementation: the case of Fluconazole. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
39	The role of glutathione conjugation on the transcellular transport process of PEGylated liposomes across the blood brain barrier. International Journal of Pharmaceutics, 2022, 626, 122152.	5.2	3
40	Approaches of formulation bridging in support of orally administered drug product development. International Journal of Pharmaceutics, 2022, , 122380.	5.2	0
41	Regulatory utility of physiologicallyâ€based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 585-597.	2.5	5
42	Polyols Permeability on Caco-2 Cells and Their Effects on Transport of Low-Permeability Drugs. Future Pharmacology, 2023, 3, 229-237.	1.8	0
43	Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs. Chemical and Pharmaceutical Bulletin, 2023, 71, 213-219.	1.3	1
44	Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs. Pharmaceutics, 2023, 15, 2366.	4.5	0
45	Challenges in Permeability Assessment for Oral Drug Product Development. Pharmaceutics, 2023, 15, 2397.	4.5	1
46	Application of co-precipitated glutinous rice starch as a multifunctional excipient in direct compression tablets. Heliyon, 2023, 9, e19904.	3.2	0
47	Ganciclovir nanosuspension-loaded detachable microneedles patch for enhanced drug delivery to posterior eye segment. Journal of Drug Delivery Science and Technology, 2023, 88, 104975.	3.0	1
48	Biowaiver based on biopharmaceutics classification system: Considerations and requirements. , 2023, , 100020.		0
49	Lack of Effect of Antioxidants on Biopharmaceutics Classification System (BCS) Class III Drug Permeability. Journal of Pharmaceutical Sciences, 2024, , .	3.3	Ο